Trial Profile
A Phase 3 Clinical Trial of Intravitreal Injections of Human Recombinant Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms Phoenix
- Sponsors Chengdu Kanghong Biotech
- 01 Sep 2014 New trial record